Recommendations for a third (or “booster”) dose of mumps vaccine

Beginning November 6, 2015, the Iowa Department of Public Health, the University of Iowa, and Johnson County Public Health are recommending University of Iowa students who are less than 25 years of age should be given a third (or “booster”) dose of mumps vaccine.

Students who meet the below criteria should NOT receive the MMR vaccine at this time:

1) Anyone who had a severe allergic reaction (e.g., generalized hives, swelling of the lips, tongue, or throat, difficulty breathing) following the first dose of MMR should not receive a second dose. Anyone knowing they are allergic to an MMR component (e.g., gelatin, neomycin) should not receive this vaccine.
   - This does not include reactions such as rash, hives, local redness or swelling, or fever; students with those types of previous reactions can receive the MMR vaccine.

2) Students who are immune-suppressed, including students receiving chemotherapy for cancer, students with congenital immune-insufficiency, or students receiving steroid treatment consisting of at least 20 mg/day for two weeks (or had this level of treatment discontinued within the last two weeks) should not receive the MMR.
   - This does not include topical steroids, aerosolized steroids, steroid treatment of less than 20 mg/day for two weeks, single injections of steroids, or alternated day dosing of steroids; students receiving these levels of steroids can receive the MMR vaccine.

3) Students who are pregnant or may become pregnant within one month.

4) Students who are currently ill with major or serious illness.
   - This does not include low grade fevers, upper respiratory illness such as colds, or current antibiotic use; students with minor illnesses such as these can receive the MMR vaccine.

5) History of thrombocytopenia or thrombocytopenic purpura.

Students who meet the below criteria MAY not be able to receive the MMR vaccine at this time, unless further assessment determines the interval from previous vaccine or antibody-containing blood product was sufficient:

6) Students with recent receipt of a live virus vaccine should defer vaccination until 28 days after receipt of the live virus vaccine. (Live virus vaccines include varicella or chickenpox vaccine, yellow fever vaccine, MMR, or live flu vaccines like “FluMist”).

7) Students who have recent receipt (within the previous 11 months) of antibody-containing blood product.

8) Specific interval needed between receipt of these products and MMR vaccine depends upon type of product.

Students with additional questions about receiving the MMR vaccine may contact their personal health care provider or the medical staff at vaccine clinics.